LONDON (Alliance News) - ValiRx PLC said Thursday it has been granted a new patent by the Japanese Patent Office, covering a means for diagnosing and monitoring patients using biomarker testing for B-cell lymphomas and its prognostic outcome.
The patent is based around the NAV3 gene, which can be used to detect pre-malignant cells at the stage where tumour development is only about to start, and for a test to find cancer cells in tissue or samples.
"The grant of this latest patent not only further extends our global geographic patent coverage, but it continues to endorse the board's decision to establish ValiFinn and our Finnish biomarkers business to capitalise on the increasingly fast use of biomarkers in oncology therapeutics. This continues to be one of the biggest areas of application with a main emphasis on predictive and personalised medicine, but also a key, growing and essential market for early diagnosis and tumour onset," said Chief Executive Officer Satu Vainikka in a statement.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
ValiRx (VAL)